Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.

Guillermo Drelichman,Nicolás Fernández Escobar,Nora Basack,Luis Aversa,María Silvia Larroude, Gabriela Aguilar, Marina Szlago,Andrea Schenone, Alcyra Fynn, María Fernanda Cuello, Marcela Aznar, Ramiro Fernández,Alba Ruiz,Paola Reichel,Norberto Guelbert, Hugo Robledo,Nora Watman, Moira Bolesina,Graciela Elena, S Ernesto Veber, Graciela Pujal, Graciela Galván, Juan José Chain, Adriana Arizo,Julieta Bietti, Daniel Bar,Marta Dragosky, Marisa Marquez,Leonardo Feldman, Katja Muller,Sandra Zirone, Greogorio Buchovsky, Victoria Lanza,Alba Sanabria, Ignacio Fernández, Rossana Jaureguiberry, Marcelo Contte, Angie Barbieri María, Alejandra Maro, Graciela Zárate, Gabriel Fernández,María Cristina Rapetti, Hugo Donato, Adriana Degano,Gustavo Kantor, Roberto Albina, María Á Lvarez Bollea, María Brun, Viviana Bacciedoni,Francis Del Río,Bárbara Soberón, Nazario Boido, Maya Schweri,Sandra Borchichi, Victoria Welsh, Marcela Corrales,Alejandra Cedola, Analía Carvani,Blanca Diez, Lucía Richard, Ccecilia Baduel,Gabriela Nuñez, Rubén Colimodio, Lucía Barazzutti, Hugo Medici, Susana Meschengieser, Germán Damiani, María Nucifora, Beatriz Girardi,Sergio Gómez, Maura Papucci, David Verón, Luis Quiroga, Gustavo Carro, Patricia De Ambrosio, José Ferro,Marcelo Pujol, Cristina Cabral Castella, Liliana Franco, Gisela Nisnovich, María Veloso, Isabel Pacheco, Mario Savarino, Andrés Marino, José Luis Saavedra

AMERICAN JOURNAL OF HEMATOLOGY(2016)

引用 12|浏览4
暂无评分
摘要
Patients with Gaucher type 1 (GD1) throughout Argentina were enrolled in the Argentine bone project to evaluate bone disease and its determinants. We focused on presence and predictors of bone lesions (BL) and their relationship to therapeutic goals (TG) with timing and dose of enzyme replacement therapy (ERT). A total of 124 patients on ERT were enrolled in a multi-center study. All six TG were achieved by 82% of patients: 70.1% for bone pain and 91.1% for bone crisis. However, despite the fact that bone TGs were achieved, residual bone disease was present in 108 patients on ERT (87%) at time 0. 16% of patients showed new irreversible BL (bone infarcts and avascular osteonecrosis) despite ERT, suggesting that they appeared during ERT or were not detected at the moment of diagnosis. We observed 5 prognostic factors that predicted a higher probability of being free of bone disease: optimal ERT compliance; early diagnosis; timely initiation of therapy; ERT initiation dose ≥45 UI/kg/EOW; and the absence of history of splenectomy. Skeletal involvement was classified into 4 major phenotypic groups according to BL: group 1 (12.9%) without BL; group 2 (28.2%) with reversible BL; group 3 (41.9%) with reversible BL and irreversible chronic BL; and group 4 (16.9%) with acute irreversible BL. Our study identifies prognostic factors for achieving best therapeutic outcomes, introduces new risk stratification for patients and suggests the need for a redefinition of bone TG. Am. J. Hematol. 91:E448-E453, 2016. © 2016 Wiley Periodicals, Inc.
更多
查看译文
关键词
gaucher disease,skeletal involvement,disease patients
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要